Form 4 Filing for Cue Biopharma, Inc.

Colin Sandercock, SVP, General Counsel of Cue Biopharma, Inc., acquired 200,000 stock options on April 9, 2026. These options have an exercise price of $0.29 and are exercisable over four years, with 25% vesting after one year and the remainder vesting semi-annually thereafter. The options are for the company's Common Stock, which has a post-transaction share count of 200,000. The filing indicates this is a direct ownership acquisition.